Patent Application
20170101675
High-throughput sequencing has become a basic support technology for essentially all areas of modern biology, from arenas as disparate as ecology and evolution to gene discovery and personalized medicine. Through the use of massively parallel sequencing in all its varieties, it is possible to identify homology among genes throughout the tree of life, to detect single nucleotide polymorphisms (SNPs), copy number variants, and genomic rearrangements in individual humans; to characterize in detail the transcriptome and its transcription factor binding sites; and to provide a detailed and even global view of the epigenome (Hawkins et al. 2010; Morozova et al. 2009; Park et al. 2009).
In order to move the field of personalized medicine forward, it will be essential to garner complete genotype and phenotype information for representative samples of all geo-ethnic population groups, including individuals presenting with a broad range of complex diseases. Having such a compendium of data will eventually permit physicians to tailor treatment to each patient, taking into account genetic factors controlling their ability to tolerate and respond to different pharmaceuticals. This will require, however, the cost of whole genome sequencing to be in the range of most other medical tests, generally taken to be $1,000 or less, and to have a lower error rate per base than the frequency of all but the rarest SNPs (<1 in 10,000) (Fuller et al. 2009; Ng et al. 2010; Shen et al. 2010).
A variety of recent so-called “next generation” sequencing technologies have brought down the cost of sequencing a genome with relatively high accuracy close to $100,000, but this is still prohibitive for health care systems even in the most affluent countries. Further efficiencies in current technologies and the introduction of breakout technologies are required to move the field to the $1,000 goal. Among the “next generation” sequencing technologies, the most popular has been the sequencing by synthesis (SBS) strategy (Fuller et al. 2009) which underlies such diverse instruments as those commercialized or in development by companies such as Roche, Illumina, Helicos, and Intelligent BioSystems. One successful SBS approach involves the use of fluorescently labeled nucleotide reversible terminators (NRTs) (Ju et al. 2003; Li et al. 2003; Ruparel et al. 2005; Seo et al. 2005; Ju et al. 2006). These are modified dNTPs (A, C, T/U and G) that have both a base-specific fluorophore and a moiety blocking the 3′ hydroxyl group of the sugar and thereby impeding its extension by the next nucleotide attached to each dNTP via a chemically, enzymatically, or photo-cleavable bond. This permits one to interrupt the polymerase reaction, determine the base incorporated according to the color of the attached fluorescent tag, and then remove both the fluor and the 3′-OH blocking group, to permit one more base to be added. The importance of the use of NRTs is that they greatly reduce the possibility of read-ahead due to the addition of more than one nucleotide, especially with the use of intermediate synchronization strategies. Both Roche's pyrosequencing approach (Ronaghi et al. 1998) and Helicos' use of “virtual” terminators (Bowers et al. 2009; Harris et al. 2008) require the addition of each base, one by one, followed by a readout that is indirect (light production in the former), or direct but single color (in the latter). Despite the undeniable power of these methods (long read length for Roche, single molecule capability for Helicos), the methods have difficulty in accurately decoding homopolymer stretches longer than ˜4 or 5 bases (Ronaghi et al. 2001). Further, pyrosequencing suffers from false positives, as free dNTPs will spontaneously decompose in solution, releasing a pyrophosphate (Gerstein 2001), producing a signal.
Recently, Ion Torrent, Inc., has described sequencing strategies in which the proton released as each nucleotide is incorporated into the DNA chain is captured by an ion sensor and digitized using semiconductor technology (Anderson et al. 2009; Rothberg et al. 2011). Again, however, since this output is identical no matter which of the four nucleotides is incorporated, because these strategies use natural nucleotides, this necessitates the base-by-base addition strategy, with its inherent difficulty in achieving accurate reads through homopolymeric base runs.
An SBS method has been described in which each nucleotide has a unique Raman spectroscopy peak, wherein determination of the wavenumber of the Raman peak is used to identify an incorporated nucleotide analogue (PCT International Application Publication No. WO 2012/162429, which is hereby incorporated by reference). However, using Raman spectroscopy to detect and identify nucleotide analogues suffers from low sensitivity inherent in this technique.
The invention is directed to a method for determining the identity of a nucleotide residue of a single-stranded DNA in a solution comprising:
The invention is further directed to a method for determining the sequence of consecutive nucleotide residues in a single-stranded DNA in a solution comprising:
The invention is further directed to a method for determining the identity of a nucleotide residue of a single-stranded RNA in a solution comprising:
The invention is further directed to a method for determining the sequence of consecutive nucleotide residues in a single-stranded RNA in a solution comprising:
The invention is further directed to a method for determining the identity of a nucleotide residue of a single-stranded RNA in a solution comprising:
The invention is further directed to a method for determining the sequence of consecutive nucleotide residues in a single-stranded RNA in a solution comprising:
The present invention is directed to a method for determining the identity of a nucleotide residue of a single-stranded DNA in a solution comprising:
The present invention is further directed to a method for determining the sequence of consecutive nucleotide residues in a single-stranded DNA in a solution comprising:
In one embodiment of any of the inventions described herein, R′ is —CH2N3.
In another embodiment of any of the inventions described herein, R′ is a substituted hydrocarbyl, and is a nitrobenzyl. In a further embodiment, R′ is a 2-nitrobenzyl.
In another embodiment of any of the inventions described herein, R′ is a hydrocarbyl, and is allyl (—CH2—CH═CH2).
In one embodiment of any of the inventions described herein, the DNA is in a solution in a reaction chamber disposed on a sensor which is (i) formed in a semiconductor substrate and (ii) comprises a field-effect transistor or chemical field-effect transistor configured to provide at least one output signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or a DNA extension product.
In another embodiment of any of the inventions described herein, the reaction chamber is one of a plurality of reaction chambers disposed on a sensor array formed in a semiconductor substrate and comprised of a plurality of sensors, each reaction chamber being disposed on at least one sensor and each sensor of the array comprising a field-effect transistor configured to provide at least one output signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or a DNA extension product.
In another embodiment of any of the inventions described herein, the reaction chamber is one of a plurality of reaction chambers disposed on a sensor array formed in a semiconductor substrate and comprised of a plurality of sensors, each reaction chamber being disposed on at least one sensor and each sensor of the array comprising a chemical field-effect transistor configured to provide at least one output electrical signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or a DNA extension product. In another embodiment, said sensors of said array each occupy an area of 100 μm or less and have a pitch of 10 μm or less and wherein each of said reaction chambers has a volume in the range of from 1 μm3 to 1500 μm3. In another embodiment, each of said reaction chambers contains at least 105 copies of the single-stranded DNA in the solution. In another embodiment, said plurality of said reaction chambers and said plurality of said sensors are each greater in number than 256,000.
In another embodiment of any of the inventions described herein, single-stranded DNA(s) in the solution are attached to a solid substrate. In another embodiment of any of the inventions described herein, a primer in the solution is attached to a solid substrate. In an embodiment, the single-stranded DNA or primer is attached to a solid substrate via a polyethylene glycol molecule. In a further embodiment, the solid substrate is azide-functionalized. In an embodiment, the DNA or primer is attached to a solid substrate via an azido linkage, an alkynyl linkage, or biotin-streptavidin interaction. In an embodiment, the DNA or primer is alkyne-labeled.
In another embodiment of any of the inventions described herein, the DNA or primer is attached to a solid substrate which is in the form of a chip, a bead, a well, a capillary tube, a slide, a wafer, a filter, a fiber, a porous media, a matrix, a porous nanotube, or a column. In another embodiment, the DNA or primer is attached to a solid substrate which is a metal, gold, silver, quartz, silica, a plastic, polypropylene, a glass, nylon, or diamond. In another embodiment, the DNA or primer is attached to a solid substrate which is a porous non-metal substance to which is attached or impregnated a metal or combination of metals. In another embodiment, the DNA or primer is attached to a solid substrate which is in turn attached to a second solid substrate. In a further embodiment, the second solid substrate is a chip.
In another embodiment of any of the inventions described herein, 1×109 or fewer copies of the DNA or primer are attached to the solid substrate. In further embodiments, 1×108 or fewer, 2×107 or fewer, 1×107 or fewer, 1×106 or fewer, 1×104 or fewer, or 1,000 or fewer copies of the DNA or primer are attached to the solid substrate.
In another embodiment of any of the inventions described herein, 10,000 or more copies of the DNA or primer are attached to the solid substrate. In further embodiments, 1×107 or more, 1×108 or more, or 1×109 or more copies of the DNA or primer are attached to the solid substrate.
In another embodiment of any of the inventions described herein, the DNA or primer are separated in discrete compartments, wells, or depressions on a solid surface.
In another embodiment, in each dNTP analogue, R′ has the structure:
In another embodiment, in each dNTP analogue R′ has the structure:
In one embodiment, the method is performed in parallel on a plurality of single-stranded DNAs. In another embodiment, the single-stranded DNAs are templates having the same sequence. In another embodiment, the method further comprises contacting the plurality of single-stranded DNAs or templates after the residue of the nucleotide residue has been determined in step (b), or (c), as appropriate, with a dideoxynucleotide triphosphate which is complementary to the nucleotide residue which has been identified, so as to thereby permanently cap any unextended primers or unextended DNA extension products.
In an embodiment of any of the methods described herein, the single-stranded DNA is amplified from a sample of DNA prior to step (a). In an embodiment of the methods described herein the single-stranded DNA is amplified by polymerase chain reaction.
In an embodiment of any of the inventions described herein, UV light is used to treat the R′ group of a dNTP analogue incorporated into a primer or DNA extension product so as to photochemically cleave the moiety attached to the 3′-O so as to replace the 3′-O—R′ with a 3′-OH. In a further embodiment, the moiety is a 2-nitrobenzyl moiety.
The invention is further directed to a method for determining the identity of a nucleotide residue of a single-stranded RNA in a solution comprising:
The invention is further directed to a method for determining the sequence of consecutive nucleotide residues in a single-stranded RNA in a solution comprising:
In one embodiment of any of the inventions described herein, R′ is —CH2N3.
In another embodiment of any of the inventions described herein, R′ is a substituted hydrocarbyl, and is a nitrobenzyl. In a further embodiment, R′ is a 2-nitrobenzyl.
In another embodiment of any of the inventions described herein, R′ is a hydrocarbyl, and is allyl (—CH2—CH═CH2).
In one embodiment of any of the inventions described herein, the RNA is in a solution in a reaction chamber disposed on a sensor which is (i) formed in a semiconductor substrate and (ii) comprises a field-effect transistor or chemical field-effect transistor configured to provide at least one output signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or an RNA extension product.
In another embodiment of any of the inventions described herein, the reaction chamber is one of a plurality of reaction chambers disposed on a sensor array formed in a semiconductor substrate and comprised of a plurality of sensors, each reaction chamber being disposed on at least one sensor and each sensor of the array comprising a field-effect transistor configured to provide at least one output signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or an RNA extension product.
In another embodiment of any of the inventions described herein, the reaction chamber is one of a plurality of reaction chambers disposed on a sensor array formed in a semiconductor substrate and comprised of a plurality of sensors, each reaction chamber being disposed on at least one sensor and each sensor of the array comprising a chemical field-effect transistor configured to provide at least one output electrical signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or an RNA extension product. In another embodiment, said sensors of said array each occupy an area of 100 μm or less and have a pitch of 10 μm or less and wherein each of said reaction chambers has a volume in the range of from 1 μm3 to 1500 μm3. In another embodiment, each of said reaction chambers contains at least 105 copies of the single-stranded RNA in the solution. In another embodiment, said plurality of said reaction chambers and said plurality of said sensors are each greater in number than 256,000.
In another embodiment of any of the inventions described herein, single-stranded RNA(s) in the solution are attached to a solid substrate. In another embodiment of any of the inventions described herein, a primer in the solution is attached to a solid substrate. In an embodiment, the single-stranded RNA or primer is attached to a solid substrate via a polyethylene glycol molecule. In a further embodiment, the solid substrate is azide-functionalized. In an embodiment, the RNA or primer is attached to a solid substrate via an azido linkage, an alkynyl linkage, or biotin-streptavidin interaction. In an embodiment, the RNA or primer is alkyne-labeled.
In another embodiment of any of the inventions described herein, the RNA or primer is attached to a solid substrate which is in the form of a chip, a bead, a well, a capillary tube, a slide, a wafer, a filter, a fiber, a porous media, a matrix, a porous nanotube, or a column. In another embodiment, the RNA or primer is attached to a solid substrate which is a metal, gold, silver, quartz, silica, a plastic, polypropylene, a glass, nylon, or diamond. In another embodiment, the RNA or primer is attached to a solid substrate which is a porous non-metal substance to which is attached or impregnated a metal or combination of metals. In another embodiment, the RNA or primer is attached to a solid substrate which is in turn attached to a second solid substrate. In a further embodiment, the second solid substrate is a chip.
In another embodiment of any of the inventions described herein, 1×109 or fewer copies of the RNA or primer are attached to the solid substrate. In further embodiments, 1×108 or fewer, 2×107 or fewer, 1×107 or fewer, 1×106 or fewer, 1×104 or fewer, or 1,000 or fewer copies of the RNA or primer are attached to the solid substrate.
In another embodiment of any of the inventions described herein, 10,000 or more copies of the RNA or primer are attached to the solid substrate. In further embodiments, 1×107 or more, 1×108 or more, or 1×109 or more copies of the RNA or primer are attached to the solid substrate.
In another embodiment of any of the inventions described herein, the RNA or primer are separated in discrete compartments, wells, or depressions on a solid surface.
In another embodiment, in each rNTP analogue, R′ has the structure:
where Rx is, independently, a C1-C5 alkyl, a C2-C5 alkenyl, or a C2-C5 alkynyl, which is substituted or unsubstituted and which has a mass of less than 300 daltons, or H, wherein the wavy line indicates the point of attachment to the 3′ oxygen atom.
In another embodiment, the rNTP analogue R′ has the structure:
In one embodiment, the method is performed in parallel on a plurality of RNAs. In another embodiment, the RNAs are templates having the same sequence. In another embodiment, the method further comprises contacting the plurality of RNAs or templates after the residue of the nucleotide residue has been determined in step (b), or (c), as appropriate, with a dinucleotide triphosphate which is complementary to the nucleotide residue which has been identified, so as to thereby permanently cap any unextended primers or unextended RNA extension products.
In an embodiment of any of the methods described herein, the single-stranded RNA is amplified from a sample of RNA prior to step (a). In a further embodiment the single-stranded RNA is amplified by reverse transcriptase polymerase chain reaction.
In an embodiment of any of the inventions described herein, UV light is used to treat the R′ group of an rNTP analogue incorporated into a primer or RNA extension product so as to photochemically cleave the moiety attached to the 3′-O so as to replace the 3′-O—R′ with a 3′-OH. In a further embodiment, the moiety is a 2-nitrobenzyl moiety.
The invention is further directed to a method for determining the identity of a nucleotide residue of a single-stranded RNA in a solution comprising:
The invention is further directed to a method for determining the sequence of consecutive nucleotide residues in a single-stranded RNA in a solution comprising:
In one embodiment of any of the inventions described herein, R′ is —CH2N3.
In another embodiment of any of the inventions described herein, R′ is a substituted hydrocarbyl, and is a nitrobenzyl. In a further embodiment, R′ is a 2-nitrobenzyl.
In another embodiment of any of the inventions described herein, R′ is a hydrocarbyl, and is allyl (—CH2—CH═CH2).
In one embodiment of any of the inventions described herein, the RNA is in a solution in a reaction chamber disposed on a sensor which is (i) formed in a semiconductor substrate and (ii) comprises a field-effect transistor or chemical field-effect transistor configured to provide at least one output signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or a DNA extension product.
In another embodiment of any of the inventions described herein, the reaction chamber is one of a plurality of reaction chambers disposed on a sensor array formed in a semiconductor substrate and comprised of a plurality of sensors, each reaction chamber being disposed on at least one sensor and each sensor of the array comprising a field-effect transistor configured to provide at least one output signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or a DNA extension product.
In another embodiment of any of the inventions described herein, the reaction chamber is one of a plurality of reaction chambers disposed on a sensor array formed in a semiconductor substrate and comprised of a plurality of sensors, each reaction chamber being disposed on at least one sensor and each sensor of the array comprising a chemical field-effect transistor configured to provide at least one output electrical signal in response to an increase in hydrogen ion concentration of the solution resulting from the formation of a phosphodiester bond between a nucleotide triphosphate or nucleotide triphosphate analogue and a primer or a DNA extension product. In another embodiment, said sensors of said array each occupy an area of 100 μm or less and have a pitch of 10 μm or less and wherein each of said reaction chambers has a volume in the range of from 1 μm3 to 1500 μm3. In another embodiment, each of said reaction chambers contains at least 105 copies of the single-stranded RNA in the solution. In another embodiment, said plurality of said reaction chambers and said plurality of said sensors are each greater in number than 256,000.
In another embodiment of any of the inventions described herein, single-stranded RNA(s) in the solution are attached to a solid substrate. In an embodiment, the single-stranded RNA or primer is attached to a solid substrate via a polyethylene glycol molecule. In a further embodiment, the solid substrate is azide-functionalized. In an embodiment, the RNA or primer is attached to a solid substrate via an azido linkage, an alkynyl linkage, or biotin-streptavidin interaction. In an embodiment, the RNA or primer is alkyne-labeled.
In another embodiment of any of the inventions described herein, the RNA or primer is attached to a solid substrate which is in the form of a chip, a bead, a well, a capillary tube, a slide, a wafer, a filter, a fiber, a porous media, a matrix, a porous nanotube, or a column. In another embodiment, the RNA or primer is attached to a solid substrate which is a metal, gold, silver, quartz, silica, a plastic, polypropylene, a glass, nylon, or diamond. In another embodiment, the RNA or primer is attached to a solid substrate which is a porous non-metal substance to which is attached or impregnated a metal or combination of metals. In another embodiment, the RNA or primer is attached to a solid substrate which is in turn attached to a second solid substrate. In a further embodiment, the second solid substrate is a chip.
In another embodiment of any of the inventions described herein, 1×109 or fewer copies of the RNA or primer are attached to the solid substrate. In further embodiments, 1×108 or fewer, 2×107 or fewer, 1×107 or fewer, 1×106 or fewer, 1×104 or fewer, or 1,000 or fewer copies of the RNA or primer are attached to the solid substrate.
In another embodiment of any of the inventions described herein, 10,000 or more copies of the RNA or primer are attached to the solid substrate. In further embodiments, 1×107 or more, 1×108 or more, or 1×109 or more copies of the RNA or primer are attached to the solid substrate.
In another embodiment of any of the inventions described herein, the RNA or primer are separated in discrete compartments, wells, or depressions on a solid surface.
In another embodiment, in each dNTP analogue, R′ has the structure:
In another embodiment, in each dNTP analogue, R′ has the structure:
In one embodiment, the method is performed in parallel on a plurality of single-stranded RNAs. In another embodiment, the single-stranded RNAs are templates having the same sequence. In another embodiment, the method further comprises contacting the plurality of single-stranded RNAs or templates after the residue of the nucleotide residue has been determined in step (b), or (c), as appropriate, with a dideoxynucleotide triphosphate which is complementary to the nucleotide residue which has been identified, so as to thereby permanently cap any unextended primers or unextended DNA extension products.
In an embodiment of any of the methods described herein, the single-stranded RNA is amplified from a sample of RNA prior to step (a). In a further embodiment the single-stranded RNA is amplified by reverse transcriptase polymerase chain reaction.
In an embodiment of any of the inventions described herein, UV light is used to treat the R′ group of a dNTP analogue incorporated into a primer or DNA extension product so as to photochemically cleave the moiety attached to the 3′-O so as to replace the 3′-O—R′ with a 3′-OH. In a further embodiment, the moiety is a 2-nitrobenzyl moiety.
Examples of attaching nucleic acids to solid substrates, or immobilization of nucleic acids, are described in Immobilization of DNA on Chips II, edited by Christine Wittmann (2005), Springer Verlag, Berlin, which is hereby incorporated by reference.
Ion sensitive field effect transistors (FET) and methods and apparatus for measuring H+ generated by sequencing by synthesis reactions using large scale FET arrays are known in the art and described in U.S. Patent Application Publication Nos. US 20100035252, US 20100137143, US 20100188073, US 20100197507, US 20090026082, US 20090127589, US 20100282617, US 20100159461, US20080265985, US 20100151479, US 20100255595, U.S. Pat. Nos. 7,686,929 and 7,649,358, and PCT International Publication Nos. WO/2009/158006 A3, WO/2008/076406 A2, WO/2010/008480 A2, WO/2010/008480 A3, WO/2010/016937 A2, WO/2010/047804 A1, and WO/2010/016937 A3, the contents of each of which are hereby incorporated by reference in their entirety.
As used herein, “hydrocarbon” refers to a compound containing hydrogen and carbon. A “hydrocarbyl” refers to a hydrocarbon which has had one hydrogen removed. Hydrocarbyls may be unsubstituted or substituted. For example, hydrocarbyls may include alkyls (such as methyl or ethyl), alkenyls (such as ethenyl and propenyl), alkynyls (such as ethynyl and propynyl), and phenyls (such as benzyl).
As used herein, “alkyl” includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and may be unsubstituted or substituted. Thus, C1-Cn as in “C1-Cn alkyl” is defined to include groups having 1, 2, . . . , n−1 or n carbons in a linear or branched arrangement. For example, a “C1-C5 alkyl” is defined to include groups having 1, 2, 3, 4, or 5 carbons in a linear or branched arrangement, and specifically includes methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, and pentyl.
As used herein, “alkenyl” refers to a non-aromatic hydrocarbon radical, straight or branched, containing at least 1 carbon to carbon double bond, and up to the maximum possible number of non-aromatic carbon-carbon double bonds may be present, and may be unsubstituted or substituted. For example, “C2-C5 alkenyl” means an alkenyl radical having 2, 3, 4, or 5, carbon atoms, and up to 1, 2, 3, or 4, carbon-carbon double bonds respectively. Alkenyl groups include ethenyl, propenyl, and butenyl.
As used herein, “alkynyl” refers to a hydrocarbon radical straight or branched, containing at least 1 carbon to carbon triple bond, and up to the maximum possible number of non-aromatic carbon-carbon triple bonds may be present, and may be unsubstituted or substituted. Thus, “C2-C5 alkynyl” means an alkynyl radical having 2 or 3 carbon atoms and 1 carbon-carbon triple bond, or having 4 or 5 carbon atoms and up to 2 carbon-carbon triple bonds. Alkynyl groups include ethynyl, propynyl and butynyl.
As used herein, “substituted” refers to a functional group as described above such as an alkyl, or a hydrocarbyl, in which at least one bond to a hydrogen atom contained therein is replaced by a bond to non-hydrogen or non-carbon atom, provided that normal valencies are maintained and that the substitution(s) result(s) in a stable compound. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
Non-limiting examples of substituents include the functional groups described above, —NO2, and, for example, N, e.g. so as to form —CN.
As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.
A—Adenine;
C—Cytosine;
DNA—Deoxyribonucleic acid;
G—Guanine;
RNA—Ribonucleic acid;
T—Thymine;
U—Uracil; and
NRT—Nucleotide Reversible Terminator.
“Nucleic acid” shall mean, unless otherwise specified, any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. In an embodiment the nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, N.J., USA). In an embodiment the DNA or RNA is not modified. In an embodiment the DNA or RNA is modified only insofar as it is attached to a surface, such as a solid surface.
“Solid substrate” or “solid support” shall mean any suitable medium present in the solid phase to which a nucleic acid or an agent may be affixed. Non-limiting examples include chips, beads, nanopore structures and columns. In an embodiment the solid substrate or solid support can be present in a solution, including an aqueous solution, a gel, or a fluid.
“Hybridize” shall mean the annealing of one single-stranded nucleic acid to another nucleic acid based on the well-understood principle of sequence complementarity. In an embodiment the other nucleic acid is a single-stranded nucleic acid. The propensity for hybridization between nucleic acids depends on the temperature and ionic strength of their milieu, the length of the nucleic acids and the degree of complementarity. The effect of these parameters on hybridization is well known in the art (see Sambrook J, Fritsch E F, Maniatis T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, New York.). As used herein, hybridization of a primer sequence, or of a DNA extension product, to another nucleic acid shall mean annealing sufficient such that the primer, or DNA extension product, respectively, is extendable by creation of a phosphodiester bond with an available nucleotide or nucleotide analogue capable of forming a phosphodiester bond.
As used herein, unless otherwise specified, a base of a nucleotide or nucleotide analogue which is a “different type of base from the type of base” (of a reference) means the base has a different chemical structure from the other/reference base or bases. For example, a base that is “different from” adenine would include a base that is guanine, a base that is uracil, a base that is cytosine, and a base that is thymine. For example, a base that is “different from” adenine, thymine, and cytosine would include a base that is guanine and a base that is uracil.
As used herein, “primer” (a primer sequence) is a short, often chemically synthesized, oligonucleotide of appropriate length, for example about 18-24 bases, sufficient to hybridize to a target nucleic acid (e.g. a single-stranded nucleic acid) and permit the addition of a nucleotide residue thereto, or oligonucleotide or polynucleotide synthesis therefrom, under suitable conditions well-known in the art. The target nucleic acid may be self-priming. In an embodiment the primer is a DNA primer, i.e. a primer consisting of, or largely consisting of deoxyribonucleotide residues. In another embodiment the primer is an RNA primer, i.e. a primer consisting of, or largely consisting of ribonucleotide residues. The primers are designed to have a sequence which is the reverse complement of a region of template/target DNA or RNA to which the primer hybridizes. The addition of a nucleotide residue to the 3′ end of a DNA primer by formation of a phosphodiester bond results in the primer becoming a “DNA extension product.” The addition of a nucleotide residue to the 3′ end of the DNA extension product by formation of a phosphodiester bond results in a further DNA extension product. The addition of a nucleotide residue to the 3′ end of an RNA primer by formation of a phosphodiester bond results in the primer becoming an “RNA extension product.” The addition of a nucleotide residue to the 3′ end of the RNA extension product by formation of a phosphodiester bond results in a further RNA extension product. A “probe” is a primer with a detectable label or attachment.
As used herein a nucleic acid, such as a single-stranded DNA or RNA, “in a solution” means the nucleic acid is submerged in an appropriate solution. The nucleic acid in the solution may be attached to a surface, including a solid surface. Thus, as used herein, “in a solution”, unless context indicates otherwise, encompasses, for example, both a DNA free in a solution and a DNA in a solution wherein the DNA is tethered to a solid surface.
A “nucleotide residue” is a single nucleotide in the state it exists after being incorporated into, and thereby becoming a monomer of, a polynucleotide. Thus, a nucleotide residue is a nucleotide monomer of a polynucleotide, e.g. DNA, which is bound to an adjacent nucleotide monomer of the polynucleotide through a phosphodiester bond at the 3′ position of its sugar and is bound to a second adjacent nucleotide monomer through its phosphate group, with the exceptions that (i) a 3′ terminal nucleotide residue is only bound to one adjacent nucleotide monomer of the polynucleotide by a phosphodiester bond from its phosphate group, and (ii) a 5′ terminal nucleotide residue is only bound to one adjacent nucleotide monomer of the polynucleotide by a phosphodiester bond from the 3′ position of its sugar.
Because of well-understood base-pairing rules, determination of which dNTP or rNTP analogue is incorporated into a primer or DNA or RNA extension product thereby reveals the identity of the complementary nucleotide residue in the single-stranded polynucleotide that the primer or DNA or RNA extension product is hybridized to. Thus, if the dNTP analogue that was incorporated comprises an adenine, a thymine, a cytosine, or a guanine, then the complementary nucleotide residue in the single-stranded DNA is identified as a thymine, an adenine, a guanine or a cytosine, respectively. The purine adenine (A) pairs with the pyrimidine thymine (T). The pyrimidine cytosine (C) pairs with the purine guanine (G). Similarly, with regard to RNA, where the RNA is hybridized to an RNA primer, if the rNTP analogue that was incorporated comprises an adenine, a uracil, a cytosine, or a guanine, then the complementary nucleotide residue in the single-stranded RNA is identified as a uracil, an adenine, a guanine or a cytosine, respectively. Where the RNA is hybridized to a DNA primer, if the dNTP analogue that was incorporated comprises an adenine, a thymine, a cytosine, or a guanine, then the complementary nucleotide residue in the single-stranded RNA is identified as a uracil, an adenine, a guanine or a cytosine, respectively.
Incorporation into an oligonucleotide or polynucleotide (such as a primer or DNA or RNA extension strand) of a dNTP or rNTP analogue means the formation of a phosphodiester bond between the 3′ carbon atom of the 3′ terminal nucleotide residue of the polynucleotide and the 5′ carbon atom of the dNTP or rNTP analogue resulting in the loss of pyrophosphate from the dNTP or rNTP analogue.
As used herein, a deoxyribonucleotide triphosphate (dNTP) analogue, unless otherwise indicated, is a dNTP having substituted in the 3′—OH group of the sugar thereof, in place of the H atom of the 3′—OH group, or connected via a linker to the base thereof, a chemical group which is —CH2N3, or is a hydrocarbyl, or a substituted hydrocarbyl, having a mass of less than 300 daltons, and which does not prevent the dNTP analogue from being incorporated into a polynucleotide, such as DNA, by formation of a phosphodiester bond. Similarly, a deoxyribonucleotide analogue residue is a deoxyribonucleotide analogue which has been incorporated into a polynucleotide and which still comprises its chemical group which is —CH2N3, or is a hydrocarbyl, or a substituted hydrocarbyl, having a mass of less than 300 daltons. In a preferred embodiment of the deoxyribonucleotide triphosphate analogue, the chemical group is substituted in the 3′—OH group of the sugar thereof, in place of the H atom of the 3′—OH group. In a preferred embodiment of the deoxyribonucleotide analogue residue, the chemical group is substituted in the 3′—OH group of the sugar thereof, in place of the H atom of the 3′—OH group. In an embodiment the chemical group is —CH2N3.
As used herein, a ribonucleotide triphosphate (rNTP) analogue, unless otherwise indicated, is a rNTP having substituted in the 3′—OH group of the sugar thereof, in place of the H atom of the 3′—OH group, or connected via a linker to the base thereof, a chemical group which is —CH2N3, or is a hydrocarbyl, or a substituted hydrocarbyl, having a mass of less than 300 daltons, and which does not prevent the rNTP analogue from being incorporated into a polynucleotide, such as RNA, by formation of a phosphodiester bond. Similarly, a ribonucleotide analogue residue is a ribonucleotide analogue which has been incorporated into a polynucleotide and which still comprises its chemical group which is —CH2N3, or is a hydrocarbyl, or a substituted hydrocarbyl, having a mass of less than 300 daltons. In a preferred embodiment of the ribonucleotide triphosphate analogue, the chemical group is substituted in the 3′—OH group of the sugar thereof, in place of the H atom of the 3′—OH group. In a preferred embodiment of the ribonucleotide analogue residue, the chemical group is substituted in the 3′—OH group of the sugar thereof, in place of the H atom of the 3′—OH group. In an embodiment the chemical group is —CH2N3.
It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
In choosing the compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. R1, Rx, etc. are to be chosen in conformity with well-known principles of chemical structure connectivity.
It is understood that where radicals are represented herein by structure, the point of attachment to the main structure is represented by a wavy line.
In the compound structures depicted herein, hydrogen atoms, except on ribose and deoxyribose sugars, are generally not shown. However, it is understood that sufficient hydrogen atoms exist on the represented carbon atoms to satisfy the octet rule.
Where a range of values is provided, unless the context clearly dictates otherwise, it is understood that each intervening integer of the value, and each tenth of each intervening integer of the value, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding (i) either or (ii) both of those included limits are also included in the invention.
All combinations of the various elements described herein are within the scope of the invention. All sub-combinations of the various elements described herein are also within the scope of the invention.
This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.
There are a number of innovative aspects to the present invention. For example, the combination of the ion sensing strategy and the sequencing-by-synthesis approach using NRTs (Ju et al. 2003; Li et al. 2003; Ruparel et al. 2005; Seo et al. 2005; Ju et al. 2006) is a novel use of disparate sequencing paradigms to produce a hybrid approach that is very low cost, has good sensitivity, avoids false positive signals caused by spontaneous NTP depyrophosphorylation, and at the same time is as accurate as any of the available sequencing strategies.
Here it is disclosed that NRTs can be exploited for ion sensing SBS because: (1) NRTs display specificity and good processivity in polymerase extension; (2) NRTs permit the ion-sensing step to address single base incorporation, overcoming the complications of multiple base incorporation in homopolymer runs of different lengths; (3) synthesis of several alternative sets of NRTs with assorted blocking groups on the 3′-OH and elsewhere in the deoxyribose allows selection of the best NRTs with regard to speed and specificity of incorporation and ease of removal of the blocking group, while maintaining compatibility with DNA stability and ion sensing requirements (Li et al. 2003; Ruparel et al. 2005; Seo et al. 2005; Ju et al. 2006); (4) NRTs provide modified nucleotides that are identical to normal nucleotides after blocking group cleavage, thus allowing longer reads to be achieved; and (5) absence of fluorescent tags on the modified nucleotides increases polymerase incorporation efficiency, greatly lowering the cost of their synthesis, and removing the need to account for background fluorescence.
In the past, high-throughput DNA sequencing was accomplished by taking advantage of the automation possibilities afforded by the Sanger sequencing approach, relative to the competing chemical sequencing strategy (Sanger et al. 1977). Although use of 4-color fluorescent tags and capillary instruments enabled quite high throughput (Ju et al. 1995; Smith et al. 1986), up to >600-base reads every couple of hours per instrument, the DNA preparation procedures needed for whole genome sequencing were economically prohibitive, often necessitating DNA cloning and clone storage. Recent strategies utilizing either sequencing by synthesis (Roche pyrosequencing and Illumina instruments) or sequencing by hybridization and ligation (ABI's SOLID™ platform) have overcome this obstacle by taking advantage of variations on polony PCR (on beads or directly on sequencing chips) (Wheeler et al. 2008; Bentley et al. 2008; McKernan et al. 2009), and at the same time taken advantage of miniaturization strategies to allow millions of reads at the same time, dwarfing essentially all the advantages of the Sanger approach except its ability to generate fairly long reads. Still newer strategies endorsed by Helicos and Pacific Sciences have approached single-molecule sequencing, though at some cost to accuracy (Harris et al. 2008; Eid et al. 2008). Other options such as the use of nanopores to discriminate released nucleotides or the sequence of intact DNA chains are still being assessed (Branton et al. 2008).
For the sequencing by synthesis strategies, there are two general schemes that depend on the nature of the detection strategy. With detection of a single signal (light, a fluorescent dye, or a pH change in the case of Roche 454, Helicos, and Ion Torrent, respectively) upon the incorporation of each nucleotide, it is necessary to add each base one by one, and score the incorporation based on whether an output signal was generated. Such methods can reduce reagent cost and simplify the instrument design, but have lower overall accuracy. In contrast, methods that utilize multiple output signals (e.g. 4 fluorescent dyes, one for each of the bases of DNA), while involving more expensive reagents, can increase accuracy, particularly if background signals are reduced or computationally subtracted. Several of these methods, especially those of the first design, utilize standard dNTPs for incorporation and measure byproducts of the formation of the phosphodiester bond. A downside of this approach is difficulty in interpreting signals in homopolymer stretches. Even if only one of the dNTPs is added at a time, one must take into account the fact that if its complementary base is present at the next several positions, it would be important but difficult to determine exactly how many of the nucleotides were added in a row. The current protocols usually take additive measures of the signal, but beyond about 3 or 4 bases, it becomes difficult to distinguish base counts.
Here, it is disclosed that the use of 3′-O-modified nucleotide reversible terminators (NRTs) overcomes these problems.
Ion Sensing During Sequencing by Synthesis:
Recently, Ion Torrent, Inc. has introduced a sequencing method that leverages the enormous progress in the semiconductor field over the past decades. The method is based on the release of a H+ ion upon creation of the phosphodiester bond in the polymerase reaction. Reactions take place in a series of wells built into a chip, and a detection layer is attached to a semiconductor chip to directly convert the resulting pH change, a chemical signal, into digital data. This technology is rapid, inexpensive, highly scalable, and uses natural nucleotides. Because there is a single signal regardless of the nucleotide that gets incorporated, it is necessary to add the four nucleotides one at a time. This can lead to difficulty in interpreting signals in homopolymer stretches, places where a nucleotide will be incorporated multiple times in the same round of the reaction. This problem is solved herein by using specific NRTs, which have been successfully used as outlined hereinbelow.
Sequencing by Synthesis with Reversible Terminators:
A series of nucleotide reversible terminators (NRTs) to accomplish sequencing by synthesis has been described in numerous publications (Ju et al. 2006; Wu et al. 2007; Guo et al. 2008). In essence this process involves the use of nucleotide analogues that have blocking groups at the 3′-OH position, which, once incorporated into DNA, prevent addition of the subsequent nucleotide. DNA templates are bound to a surface and primers are hybridized to these templates. One can then measure the incorporation of a particular NRT onto the priming strand, due to its complementarity to a nucleotide on the template strand, by virtue of specific fluorophores attached to each base. These blocking groups and fluorophores can be easily removed using chemical or photo-cleavage reactions that do not damage the DNA template or primer. In this way, additional rounds of incorporation, detection and cleavage can take place. These SBS reactions are accurate, show no dephasing (reading ahead or lagging), and have relatively low background due to misincorporated nucleotides or incomplete removal of dyes.
Three different sets of 4 NRTs (
It is disclosed here that 3′-O-(2-nitrobenzyl) nucleotides are particularly useful for ion sensor measurement. They are quickly and efficiently incorporated, and photo-cleaved under conditions that do not require the presence of salts which could interfere with subsequent rounds of ion sensing. However, other modified bases are also useful. The 3′-O-azidomethyl group is particularly attractive. Not only is it efficiently incorporated, but it regenerates the natural base upon cleavage, thus does not impede subsequent nucleotide incorporation, resulting in long sequence reads (Guo et al. 2008).
Preparation of a Library of NRTs and their Evaluation in SBS Polymerase and NRT Conditions Compatible with Ion Sensing.
Preparation of Full Sets of NRTs Sufficient for all Studies in this Application:
Established methods are used to synthesize the NRTs for ion-sensing SBS evaluation (Ju et al. 2003; Ju et al. 2006; Wu et al. 2007; Guo et al. 2008).
Characterization of Utility of NRTs for Ion Sensing:
The ion dependence for 9° N, Therminator II and Therminator III polymerases (all available from New England Biolabs, Ipswich, Mass.) that support incorporation of the NRTs are determined, initially using dideoxynucleotide triphosphates (ddNTPs) for single base extension reactions. Tests are performed in solution using synthetic template/primer systems, and cleaned-up extension products subjected to MALDI-TOF mass spectroscopy (MS) to quantify product yield. A series of monovalent and divalent cation, and monovalent anion concentrations, are tested. Once the basic parameters are established with dNTPs and ddNTPs, similar assays are performed using 3′-O-(2-nitrobenzyl), 3′-O-azidomethyl, and 3′-O-allyl nucleotides, utilizing enzymes that are best able to incorporate each of these modified nucleotides. Relevant time points are used to assess the salt dependence. While the salt-independent photo-cleavage of the 2-nitrobenzyl group may have advantages for the Ion Torrent-type system, automating chemical cleavage with azidomethyl or allyl derivatives is also possible.
To test polymerase specificity in the low salt buffer systems, all four ddNTPs or ddNTP analogues are combined in the reactions. In a synthetic template-primer system it is already known which of the 4 bases should be added next, and these can each be distinguished as well-separated peaks in the mass spectra. By including two or more of the same base in a row, these spectra are examined to confirm that reactions are terminated completely after the first base. Next, the buffer system used is tested with each of the preferred polymerase/nucleotide reversible terminator combinations. Reduction of the salt concentration to low enough amounts to permit subsequent ion sensing is also tested.
NRTs Tested in Ion Sensing Platform.
When enzyme/NRT/low ion buffer systems are established, short runs of 2 or 3 base extensions are conducted on an H+ sensitive ion sensing system, such as the Ion Torrent, Inc. platform, as outlined in
Ion Sensor SBS with NRTs.
After confirmation that the ion sensing system handles a set of NRTs with good efficiency, a biological sample (a known viral or a bacterial genome) is sequenced using the combined SBS-ion sensing approach. Sequences are assembled and searched for the presence of polymorphisms or sequence errors. For example, pathogenic and non-pathogenic Legionella species can be used and a comparative analysis performed, with gene annotation as necessary.
The accuracy for homopolymer runs of more than a few bases is near perfect with the NRTs, but much lower with standard nucleotides. The need for cycles of incorporation, detection and cleavage adds additional time, but with automation and maximized efficiencies of both incorporation and deprotection, this does not outweigh the gain in accuracy. A ddNTP synchronization step can be included optionally in each or every other cycle. A sequence is assembled de novo for a low-repeat bacterial sequence. With appropriate long-range mate-pair library preparation methods, de novo and re-sequencing of eukaryotic genomes is also possible. Both long and short sequence reads are usable and the method can be employed for conducting comparative sequence analysis, genome assembly, annotation, and pathway analysis for prokaryotic and eukaryotic species.
This application claims priority of U.S. Provisional Application No. 62/000,306, filed May 19, 2014, which is incorporated herein by reference in its entirety. This application incorporates-by-reference nucleotide and/or amino acid sequences which are present in the file named “150518_0575_82337-PCT_SequenceListing_JAK.txt,” which is 1 kilobyte in size, and which was created May 18, 2015 in the IBM-PC machine format, having an operating system compatibility with MS-Windows, which is contained in the text file filed May 18, 2015 as part of this application. Throughout this application, certain publications are referenced in parentheses. Full citations for these publications may be found immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention relates.
This invention was made with government support under grant nos. HG003582 and HG005109 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US15/31358 | 5/18/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62000306 | May 2014 | US |
